Key result
SARS-CoV-2 JN.1 emergence highlights the need to evaluate population-level hybrid immunity at 11 months.
Why the study?
The current immunity against the circulating SARS-CoV-2 variant JN.1 at the population level has yet to be fully evaluated.
Population
Individuals with hybrid immunity following breakthrough infection
Design
Other
Follow-up
11 months
Authors
Loading...
Hybrid immunity yields heterogeneous, often negligible JN.1 neutralization 11 months post-BTI; leaves open whether targeted boosters can protect seniors.
The text highlights the need to evaluate population-level immunity against the highly transmissible SARS-CoV-2 JN.1 variant 11 months after breakthrough infection.
He et al. (2024) studied COVID-19. Hybrid immunity following breakthrough infection was evaluated. The abstract discusses the emergence of the SARS-CoV-2 JN.1 variant and the need to evaluate population-level hybrid immunity at 11 months, but reports no quantitative clinical data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: